In silico analysis shows a significant overlap between genes suppressed by 1,25(OH) 2 D 3 and miR-22 putative target genes. Consistently, miR-22 inhibition abrogates the 1,25(OH) 2 D 3 -mediated suppression of NELL2, OGN, HNRPH1, RERE and NFAT5 genes. In 39 out of 50 (78%) human colon cancer patients, miR-22 expression was found lower in the tumour than in the matched normal tissue and correlated directly with that of VDR. Our results indicate that miR-22 is induced by 1,25(OH) 2 D 3 in human colon cancer cells and it may contribute to its antitumour action against this neoplasia.
INTRODUCTION
Vitamin D deficiency is increasingly associated with a variety of human diseases (1, 2) . Among them, colorectal cancer is particularly important as many epidemiological studies link the high risk of developing this neoplasia to low vitamin D diet or circulating level of calcidiol (25-hydroxyvitamin D 3 ) (3, 4) . In line with this, experimental data in cultured cells and animal models show that the most active vitamin D metabolite 1a,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) exerts potent protective effects against colon cancer (and other neoplasias) (5 -7).
1,25(OH) 2 D 3 is a pleiotropic hormone that regulates many genes in numerous tissues in the organism. Its classical model of action implies the binding to, and activation of a member of the superfamily of nuclear receptors, the vitamin D receptor (VDR). VDR acts as a ligand-modulated transcription factor that binds to specific sequences (vitamin D response elements) in target genes and increases or decreases their transcription rate through the interaction with a vast array of * To whom correspondence should be addressed at: Instituto de Investigaciones Biomédicas "Alberto Sols", Arturo Duperier 4, E-28029 Madrid, Spain. co-activators, co-repressors and chromatin modifier enzymes and remodelling complexes (8, 9) . Recent data, however, indicate that a number of 1,25(OH) 2 D 3 target genes are regulated by posttranscriptional and/or posttranslational mechanisms (10) (11) (12) .
MicroRNAs (miRNAs) are short non-coding RNAs with wide gene regulatory activity at the posttranscriptional level. MiRNAs associate with several proteins in RNA silencing complexes that cause mRNA degradation or translation inhibition, or both processes (13) . In recent years, miRNAs have been shown to play key roles in cancer as they control the expression of crucial oncogenes and tumour suppressor genes and, accordingly, several miRNAs are either over-expressed or silenced affecting tumour progression and metastasis (14, 15) .
To gain insight into the action of 1,25(OH) 2 D 3 in colon cancer, we have searched for novel targets by screening with miRNAs microarrays. Among the candidate targets identified, we focused on miR-22 based on previous data, suggesting its tumour suppressor activity (16) (17) (18) (19) (20) (21) . 1,25(OH) 2 D 3 modulates cell proliferation: it usually has a mild to medium cell-type-dependent inhibitory effect, although stimulatory effects have also been reported (22, 23) . Our results show that miR-22 is induced by 1,25(OH) 2 D 3 and contributes to its inhibitory effects on the proliferation and migration of colon cancer cells. Moreover, we found that anti-miR-22 expression abrogates the regulation by 1,25(OH) 2 D 3 of the RNA levels of several target genes. Importantly, miR-22 is downregulated in a high proportion of colon tumours and its expression correlates directly with that of VDR. Together, these data show that miR-22 is a target of 1,25(OH) 2 D 3 and mediates in part its protective action against colon cancer.
RESULTS

miR-22 is induced by 1,25(OH) 2 D 3
To study whether 1,25(OH) 2 D 3 affects miRNA expression in human colon cancer, we profiled with miRNA microarrays RNA samples extracted from SW480-ADH cells that were treated for different time points either with 10 27 M 1,25(OH) 2 D 3 or the corresponding amount of vehicle (control). A series of miRNA species were consistently found to be upregulated (i.e. miR-146a, miR-22, miR-222) or downregulated (i.e. miR-203) (Fig. 1) . Data have been deposited in GEO databases (GSE34564). On the basis of its kinetics of induction and the literature reporting its tumour suppressive activity in several systems, miR-22 was chosen for an in-depth study.
Validation of microarray data was performed by quantitative real-time PCR (qRT-PCR). The level of miR-22 increased in a time-and dose-dependent manner following 1,25(OH) 2 D 3 treatment of SW480-ADH cells ( Fig. 2A and B) . Moreover, miR-22 was also induced by this hormone in five others human colon cancer cell lines (LS174T, HT29, SW1417, DLD-1, HCT116), while no induction was found in SW480-R and SW620 cells that lack VDR expression (5) (Fig. 2C) . Next, we examined whether the induction of miR-22 could be relevant for the inhibitory effect of 1,25(OH) 2 D 3 on cell proliferation and migration of colon cancer cells. To this end, we first transfected SW480-ADH and HCT116 cells with a miR-22 oligonucleotide inhibitor (anti-miR-22) or a nonsilencing control (scrambled oligonucleotide, SCR) and analysed their proliferation in the presence or absence of 1,25(OH) 2 D 3 . In both cell types, the decrease in the number of viable cells, resulting from the sum of effects on cell division and survival caused by the hormone, was blunted by the addition of anti-miR-22 but not by that of SCR oligonucleotide ( Fig. 3A and B) . Notably, in the absence of 1,25(OH) 2 D 3 , anti-miR-22 treatment did not alter cell division ( Fig. 3A and B) but, in contrast, led to an increased migratory capacity in transwell assays (2.13 + 0.3-fold, P ¼ 0.0002, for HCT116 cells; 1.75 + 0.38-fold, P ¼ 0.007, for SW480-ADH cells) ( Fig. 4A and B) . In line with this, anti-miR-22 abolished the inhibition of cell migration caused by 1,25(OH) 2 D 3 in both cell types ( Fig. 4A and B) . In all experiments, blockade of miR-22 induction by 1,25(OH) 2 D 3 using anti-miR-22 was analysed by qRT-PCR (Supplementary Material, Fig. S1 ).
miR-22 mediates the regulation of several 1,25(OH) 2 D 3 target genes
We wished to explore the putative role of miR-22 in the gene regulatory effect of 1,25(OH) 2 D 3 . To this end, we first did a comparative in silico analysis by using TargetScan (24) for predicted miR-22 targets and data from our transcriptomic studies of 1,25(OH) 2 D 3 target genes [(25) and unpublished data]. This study rendered that 9 out of 36 genes (25%) downregulated and 11 out of 93 genes (11.8%) upregulated by the Table S1 ). The comparison of these data with the predicted targets of a randomly selected group of miRs (miR-200a, miR-142-3p, miR-142-5p, miR-320a, miR-31, miR-365 and miR-34b; median of total targets of 655 and median overlap with 1,25(OH) 2 D 3 targets of only 3) revealed the statistical evidence that miR-22 targets are enriched in the 1,25(OH) 2 D 3 -treated array data set relative to other miRs.
To validate this finding, we analysed the expression of a few selected genes downregulated by 1,25(OH) 2 D 3 , such as neural tissue-specific epidermal growth factor-like repeat domaincontaining protein (NELL2), osteoglycin (OGN), heterogeneous nuclear ribonucleoprotein H1 (HNRPH1), nuclear factor of activated T cells 5 (NFAT5), caudal type homeobox 2 (CDX2) and arginine-glutamic acid dipeptide (RE) repeats (RERE) in SW480-ADH and HCT116 cells transfected with either anti-miR-22 or SCR oligonucleotides. Supporting a role of miR-22 mediating the downregulation of these genes by the hormone, in either or both cell lines, the transfection of anti-miR-22 oligonucleotides but not of SCR abrogated such inhibitory effect, except in the case of CDX2 (Fig. 5B and C) . We also studied CDH1, a gene transcriptionally upregulated by the hormone that mediates part of its effects in colon cancer cells (5, 26) . As expected from this regulation, anti-miR-22 did not affect the induction by 1,25(OH) 2 D 3 , suggesting that CDH1 mRNA may not be indeed a target of miR-22.
Expression of miR-22 in human colon tumours
Finally, we studied the expression of miR-22 in 50 matched normal and tumour samples from human colon cancer patients. In agreement with a tumour suppressive action, miR-22 expression was found downregulated in 39 out of 50 (78%) tumours when compared with normal tissue Fig. S2 ). Notably, a significant direct correlation was found between the expression of miR-22 and VDR RNA (spearman correlation coefficient, r ¼ 0.315, P ¼ 0.026) (Fig. 6B) , which suggests that the VDR-mediated induction of miR-22 observed in cultured cells probably also takes place in human colon tissue. 
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Human Supporting the consistency of these findings, they have been described in two cell lines that harbour different sets of mutations that are crucial and represent most human colon tumours: while SW480-ADH cells harbour mutated APC, TP53 and K-RAS genes, HCT116 cells express a wild-type APC but a mutated CTNNB1/b-catenin that is the alternative responsible mechanism for the aberrant activation of the Wnt canonical 
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Human Molecular Genetics, 2012, Vol. 21, No. 10 signalling pathway, a hallmark of this neoplasia. Both cell types contain a mutated K-RAS, but they differ with respect to the major tumour suppressor TP53, which is normal in HCT116 but mutated in SW480-ADH cells. Several reasons support a role of the regulation of miR-22 for 1,25(OH) 2 D 3 action in this system. First, our data show that miR-22 mediates the antiproliferative and antimigratory action of the hormone. Secondly, because the repression by 1,25(OH) 2 D 3 of certain genes that are in part dependent on miR-22 may contribute to its antitumoural action; thus, NELL2 is repressed by the antitumour agent genistein in pancreatic cancer Panc1 cells (30) , is over-expressed in Burkitt's lymphoma cells, neuronal tumours and benign prostatic hyperplasia (31) (32) (33) and contributes to the survival-promoting effects of estradiol via the extracellular signal-regulated kinase signalling pathway (34) . HNRPH1 encodes a splicing regulator that is overexpressed in colon cancer and counteracts apoptosis induced by etoposide and fluoropyrimidine anticancer drugs (35) (36) (37) . NFAT5 transcriptional activity is induced by integrin a6b4 and Src oncogene (38) , and mediates carcinoma invasion through the induction of S100A4 (39), and possibly also melanoma invasion (40) . RERE (or ATN1) encodes a nuclear receptor corepressor that is aberrantly expressed in neuroblastoma and appears to be involved also in acute myeloid leukaemia (41) . Very little relation exists between OGN and cancer; paradoxicaly, it has been proposed to decrease gelatinase activity of murine hepatocarcinoma cells (42) .
The relevance of miR-22 regulation by 1,25(OH) 2 D 3 is also supported by the tumour suppressive effects of this miRNA recently described in other systems. Thus, miR-22 suppresses cell proliferation and tumourigenicity and is downregulated in hepatocellular carcinoma (16) , represses c-Myc-binding protein, MYCBP, a positive regulator of the strong oncogene c-MYC (17) , and controls the EVI-1 oncogene in breast cancer cells (18) . Additionally, miR-22 is induced by p53 and favours p53-dependent apoptosis by targeting CDKN1A/ p21 CIP21 RNA (19) , although our data show that the induction of miR-22 by 1,25(OH) 2 D 3 is independent of p53 as it takes place in cells with either wild-type or mutant TP53 gene. Also, miR-22 suppresses the activity of nuclear factor kappa B, an important inducer of cell survival and inflammatory and tumourigenic cytokines (20) . Remarkably, miR-22 may have an anti-angiogenic effect in colon cancer via the inhibition of hypoxia inducible factor-1a expression (21) . Lastly, it has recently been reported the additive induction of miR-22 by testosterone and 1,25(OH) 2 D 3 in the prostate cancer LNCaP cell line (43) . Altogether, these data suggest that miR-22 induction may play a role in the antitumoural action of 1,25(OH) 2 D 3 .
Data obtained from human biopsies show the correlation between the expression of VDR RNA and miR-22, suggesting that 1,25(OH) 2 D 3 may also regulate miR-22 expression in vivo. Likewise, the downregulation of miR-22 concomitant to VDR silencing in tumours agrees with its tumour suppressive effects in cultured colon cancer cells.
In summary, we have identified miR-22 as a novel target of 1,25(OH) 2 D 3 that expand the range of its gene expression modulatory activity at the posttranscriptional level and may contribute to explain at least partially its protective action on this important neoplasia.
MATERIALS AND METHODS
Cells and cell culture
Human colon cancer SW480-ADH, HCT116, HT29, LS174T, DLD-1, SW620, SW1417 and SW480-R cell lines were cultured in DMEM plus 10% fetal bovine serum (Invitrogen). All experiments using 1,25(OH) 2 D 3 or isopropanol (vehicle) were performed in medium supplemented with charcoaltreated serum.
Cell proliferation and migration assays
To measure proliferation, cells (15 × 10 . Experiments were performed in triplicate. Phase-contrast images were captured with a Leica DC300 digital camera mounted on an inverted Leitz Labovert FS microscope. All images were processed using Adobe Photoshop CS4 software.
miRNA microarray analysis
Microarrays were produced in the Genomics Unit of the Spanish National Cancer Research Centre (CNIO), Spain. Briefly, NCode Multi-Species miRNA V2 probeset (Invitrogen, cat. # MIRMPS2-01) was printed on Nexterion epoxy E slides (Schott) by following manufacturer's recommendations. Probe sequences target all of the known mature miRNAs in the Sanger miRBase Sequence Database, Release 9.0. Cellular small RNA fractions were extracted with PureLink miRNA isolation kit (Invitrogen) and labelled with the 2-color LabelIT miRNA labelling system (Mirus). Extracts from cells treated with 1,25(OH) 2 D 3 or vehicle at each time point were compared in dye-swapped hybridizations. Hybridization conditions were as per Mirus' kit recommendations and microarrays were read with an Agilent G2505B scanner. Two hybridization batches were performed on a first series of cells cultured for 24, 48 or 72 h (data not shown). A last batch, in which all the samples were dye swapped in technical replicates, employed new cultures from a time series of 24, 48 and 96 h. Changes between 1,25(OH) 2 D 3 and vehicle treatments were apparent and steady but small, and statistically non-significant. Biological replication (two replicates for time points 24 and 48 h) was insufficient. Entities that showed no signs of differential expression, with absolute fold change ,1.5, were discarded from consideration. Raw data from microarray images were quantified, background subtracted and global Lowess normalized with Feature Extraction Software (Agilent). Visualization of miRNA expression data showing relatively high intensity signals was carried out by 
Quantitative RT-PCR
Total RNA (including small RNAs) from cultured cell lines was extracted using the NucleoSpinw miRNA extraction kit (Macherey-Nagel). RNA from 30 mg of tumour or normal tissue was extracted using RNeasy mini kit (Qiagen).
qRT-PCR analyses of miR-22 expression level were performed using the miRNA-specific TaqMan MicroRNA Assay Kit (Applied Biosystems). Briefly, 12.5 ng of total RNA was reversed transcribed using the corresponding RT Primer and the TaqMan MicroRNA Reverse transcription Kit (Applied Biosystems). PCR was performed on 1.33 ml of RT products by adding the TaqMan PCR primers and the iQ Supermix (Bio-Rad). RNU44 small RNA was used for normalization of input RNA/cDNA levels. VDR, NFAT5, NELL2, OGN, CDX2, CDH1, RERE and HNRPH1 RNA levels were measured using the primers listed in Supplementary Material, Table S2 and the Power SYBR w Green PCR Master Mix (Applied Biosystems). RNA expression values were normalized versus the housekeeping gene succinate dehydrogenase complex subunit A (SDHA). The reaction was performed in a CFX384 Real-Time PCR Detection System (Bio-Rad).
Patients and tumour samples
Normal and tumour tissue samples from 50 colon cancer patients were obtained immediately after surgery, immersed in RNA later (Applied Biosystems), snap-frozen in liquid nitrogen and stored at 2808C until processing. Tumours were considered sporadic cases because no clinical antecedents of Familial Adenomatous Polyposis were reported and those with clinical criteria of hereditary non-polyposis colorectal cancer (HNPCC) (Amsterdam criteria) were excluded. Tumours were examined by two different pathologists to: (i) confirm adenocarcinoma diagnosis and presence of at least 75% of tumour tissue in the sample, (ii) determine the histological level of the tumour, and (iii) verify the absence of tumour cells in normal tissue. All patients gave written informed consent. The protocol was approved by the Research Ethics Board of the Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain.
Statistical analysis
Results are expressed as mean + SD unless otherwise specified. Statistical significance was assessed by the one-way analysis of variance test with Bonferroni post-test. Differences were considered significant when P , 0.05. The single asterisk indicates P , 0.05, the double asterisk P , 0.01 and the triple asterisk P , 0.001. All statistical analyses were performed using the Prism software V5 (GraphPad software). As the tumour/normal tissue ratios of VDR and miR-22 expression were not normally distributed (KolmogorovSmirnov test, Lilliefords correction), we normalized the data distribution by using log 10 for statistical analysis. Correlations between RNA expression levels were analysed using the Spearman correlation coefficient.
